Simvastatin Plus Ezetimibe Lowers Risk of Cataract Development
Statin treatment, simvastatin plus ezetimibe, is associated with a lower risk of cataract development.
Dyslipidemia
Body Composition, Metabolism Altered in Endurance Competition
Athletes who competed in Ultraman, an endurance competition, experienced dramatic metabolic alterations, including increases in creatine kinase, C-reactive protein, aldosterone, and cortisol.
CDC: Cholesterol-Lowering Medications Underutilized
Only half of American adults who should be taking cholesterol-lowering drugs are, according to the Centers for Disease Control.
Elevated Lipoprotein(a) Levels Increase Risk for Heart Failure
Elevated levels of lipoprotein(a) may be associated with an increased risk for heart failure in the general population.
Total Cholesterol Increases; HDL-C Declines in Middle-Aged Adults
About 1 in 8 American adults continue to have high levels of total cholesterol and lower levels of high-density lipoprotein cholesterol, according to a new data brief published by the National Center for Health Statistics.
Financial Incentive for Taking Cholesterol Medications Shows Modest Benefit
Patients in a shared physician-patient incentive group achieved modest reductions in LDL-C levels.
Heart Failure Hospitalizations, CV Death Reduced With Empagliflozin
Results from the EMPA-REG OUTCOME trial showed empagliflozin reduced heart failure hospitalizations and cardiovascular deaths in patients with type 2 diabetes.
PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost
PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.
Apixaban Associated With Lower Risk for Stroke Than Aspirin in Patients With AF and Low-Risk Stroke Classification
The anticoagulant apixaban was found to increase life expectancy at a higher rate than aspirin in patients with low risk for stroke.
FDA Approves PCSK-9 Inhibitors Alirocumab and Evolocumab Based on LDL Cholesterol Reduction
The FDA approves PCSK-9 inhibitors alirocumab and evolocumab, amid cardiovascular risk debate.
- Loading...
Loading...
Next post in Hypertension
Loading... 
Loading...